|
Case no. | Sex/Age | Date and localisation of tumor manifestaion | KRAS Gly12/13 (exon2) | BRAF V600E (exon15) | Anti-EGFR therapy |
|
1 | M/51 y | 09/05 primary CRC | Gly12Val | WT | 01/07–04/07 Folfiri/Cetuximab (PD) |
11/07 small bowel metastasis | Gly12Val | WT | dead 05/08 |
|
2 | M/71 y | 11/02 soft tissue | Gly12Cys | WT | 09/04–08/05 Folfiri/Cetuximab (PR) |
03/06 mesocolon transversum metastasis | Gly12Cys | WT | |
|
3 | M/46 y | 03/07 primary CRC | WT | WT | 08/07–06/08 Folfiri/Cetuximab (PR) |
02/09 peritoneal carcinosis | WT | WT | |
|
4 | M/68 y | 11/06 primary CRC | Gly12Asp | WT | 04/07–02/08 Fufox/Cetuximab(PR) |
03/08 liver metastasis | WT | WT | |
|
5 | F/56 y | 07/08 primary CRC | Gly12Asp | WT | 07/08–09/08 Fufox/Cetuximab (PD) |
12/08 peritoneal carcinosis | Gly12Asp | WT | dead 12/08 |
|
6 | M/71 y | 12/05 primary CRC | Gly12Val | WT | 01/06–07/06 Folfiri/Cetuximab (PD) |
12/06 liver metastasis | Gly12Val | WT | dead 04/08 |
|
7 | F/58 y | 01/08 primary CRC | WT | WT | 04/08–07/08 Folfiri/Cetuximab (PD) |
07/08 peritoneal carcinosis | WT | WT | dead 07/08 |
|
8 | F/44 y | 11/07 primary CRC | WT | WT | 05/08–03/09 Folfox/Cetuximab (PR) |
12/08 peritoneal carcinosis | WT | WT | |
|
9 | F/66 y | 02/04 primary CRC | Gly12Ser | WT | 07/06–09/06 Folfox/Cetuximab (PR) |
11/05 + 04/06 liver metastasis | Gly12Ser | WT | 07/06–09/06 Folfox/Cetuximab (PD) |
11/06 lung metastasis | Gly12Ser | WT | 09/06-11/06 Folfiri/Avastin (PD) |
|
10 | M/77 y | 11/05 primary CRC | Gly13Asp | WT | 12/05–09/06 Folfox + Cetuximab (PD) |
07/06 lymph node | Gly13Asp | WT | 10/06–02/07 Folfiri + Avastin (PD) dead 05/07 |
|
11 | M/63 y | 05/07primary CRC | WT | WT | 05/07–07/08 Folfiri/Cetuximab (PR) |
01/08 liver metastasis | WT | WT | 10/08–05/09 Folfox (PR) |
06/09 liver metastasis | WT | WT | |
|
12 | M/67 y | 07/07 liver metastasis | WT | WT | 08/07–04/08 Folfox/Cetuximab (PR) |
01/08 liver metastasis | WT | WT | |
|
13 | M/59 y | 09/07 primary CRC | WT | WT | |
10/07 liver metastasis | WT | WT | 11/07–03/08 Folfiri/Cetuximab (PR) |
05/08 liver metastasis | WT | WT | |
|
14 | M/61 y | 07/02 primary CRC | WT | WT | 10/07–07/08 Folfox/Cetuximab (PR) |
05/04 liver metastasis | WT | WT | |
07/08 peritoneal carcinosis | WT | WT | Since 12/08 Folfox (PR) |
|
15 | F/68 y | 09/05 primary CRC | WT | V600E | 10/05–02/06 Folfox (PD) |
05/06 soft tissue | WT | V600E | 03/06–08/06 Folfiri/Cetuximab (PR) |
01/07 soft tissue | WT | V600E | 01/07–05/07 Cetuximab/Irinotecon (PD) dead 06/07 |
|
16 | M/75 y | 07/00 primary CRC | Gly12Asp | WT | |
07/03 lung metastasis | Gly12Asp | WT | 08/03–07/04 Folfox (PD) |
08/03 liver metastasis | | | 08/04–08/05 Folfiri (PD) |
08/05 liver metastasis | Gly12Asp | WT | 08/05–04/06 Folfiri/Cetuximab (PD) 04/06–02/07 Cetuximab+CPT-11(PD)02/07–04/07 Panitumumab (PD) |
04/07 ascites | Gly12Asp | WT | dead 05/07 |
|
17 | M/69 y | 06/02 primary CRC | Gly13Asp | WT | 06/02–09/02 Folfox (PR) 06/03–12/03 Folfox (PR) 07/04–01/06 Folfiri (PD) 03/06–05/06 Cetuximab + CPT-11 (PD) 09/06–02/07 Folfox (PD) |
07/07 mesocolon metastasis | Gly13Asp | WT | dead 09/07 |
|
18 | M/75 y | 01/04 primary CRC | Gly12Asp | WT | 06/07–10/07 Capecitabine/Cetximab (PD) |
01/08 peritoneal carcinosis | Gly12Asp | WT | dead 03/08 |
|
19 | F/61 y | 07/08 primary CRC | WT | WT | 07/08–03/09 Folfiri/Cetuximab (PR) |
05/09 liver metastasis | WT | WT | |
|
20 | M/56 y | 05/08 primary CRC | WT | WT | 06/08-12/08 Folfox/Cetuximab (PR) |
06/09 lung metastasis | WT | WT | |
|
21 | M/72 y | 09/08 primary CRC | WT | WT | 10/08-02/09 Folfiri/Cetuximab (PR) |
01/09 liver metastasis | WT | WT | |
|